Menu

BETTY: BEnign Prostatic Hyperplasia Transperineal Targeted Microwave therapY

Status

Enrolling

Conditions

Prostate Hyperplasia

Treatments

Device: 3D-Ultrasound-Guided Transperineal Microwave needle ablation of BPH

Study type

Interventional

Funder types

Other
Industry

Identifiers

NCT05443451
CRE 2022.249

Details and patient eligibility

About

This is a pilot study on applying 3D-Ultrasound-Guided Transperineal Microwave needle ablation for men with symptomatic benign prostatic hyperplasia (BPH).

Full description

This is a prospective, single centre, open-label and non-comparative trial planned on 12 patients. Patients who fit inclusion criteria would be recruited and offered microwave ablation to the enlarged prostate. The patients will be closely followed up to 6 months after treatment with serial assessment on safety and efficacy.

Enrollment

12 estimated patients

Sex

Male

Ages

50+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Age over 50 years.
  • Benign prostatic hyperplasia with prostate size 30-80 cc
  • IPSS ≥ 14
  • PSA ≤ 4 ng/mL or PSA >4 ng/mL with no evidence of suspicious lesion on mpMRI
  • Maximum urine flow rate (Qmax) ≤ 15 mL/s.
  • Post-Void Residual ≤ 150 mL.
  • Patient suitable for IV sedation and/or spinal anaesthesia and/or general anaesthesia and focal microwave ablation.
  • Informed written consent

Exclusion criteria

  • Significant intravesical median lobe hyperplasia.
  • Suspicious lesion on mpMRI prostate
  • History of prostate, bladder or urethral surgery.
  • History of prostate cancer
  • Presence of stones, bladder diverticulum and/or bladder tumor
  • History of long-term indwelling catheter.
  • Urethral stricture
  • Known coagulopathy or on anticoagulant
  • Presence of a pacemaker.
  • Active infection
  • Dysuria due to bladder dysfunction.
  • Serious medical illness, including any of the following: uncontrolled congestive heart failure, uncontrolled angina, myocardial infarction, cerebrovascular event within 6 months prior to the screening visit.
  • Neurological disorders that would impact bladder function (e.g., multiple sclerosis, Parkinson's disease, spinal cord injury).
  • Contraindications for mpMRI exam or MR contrast
  • Acute and/or chronic renal failure (GFR <50 ml/min and serum creatinine > 1.5 mg/d).
  • Patient currently participating in another interventional clinical trial.

Trial design

Primary purpose

Treatment

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

12 participants in 1 patient group

Transperineal Microwave needle ablation for symptomatic BPH
Experimental group
Treatment:
Device: 3D-Ultrasound-Guided Transperineal Microwave needle ablation of BPH

Trial contacts and locations

1

There are currently no registered sites for this trial.

Central trial contact

Peter Ka-Fung CHIU, FRCS, PhD

Timeline

Last updated: Jan 23, 2024

Start date

Sep 08, 2022 • 2 years ago

End date

Aug 31, 2024 • 7 months ago

Today

Apr 28, 2025

Sponsors of this trial

Collaborating Sponsor

Data sourced from clinicaltrials.gov